🌍 ELEM biotech’s Mariano Vázquez highlights their use in developing virtual humans for simulating clinical trials.
💻 Factors driving this trend include AI advancements and larger datasets. The regulatory environment is also becoming more favorable, supporting broader applications.
🧬 Virtual populations can expedite drug testing, especially for rare diseases.
Introduction:
The article discusses the escalating adoption of digital twin technologies within the biopharmaceutical sector and the potential applications in developing virtual human models to enhance drug testing and development processes.
- The biopharmaceutical industry is increasingly adopting digital twin technologies to improve efficiency in drug discovery and manufacturing processes.
- Regulatory changes, advancements in artificial intelligence (AI), and access to larger datasets are driving the expansion of digital twin applications.
- ELEM Biotech is leveraging digital twins to create “virtual humans” for simulating clinical trial outcomes, which can expedite the drug testing process.
- These virtual models enable testing across diverse demographics more cost-effectively, especially for rare diseases.
- The COVID-19 pandemic has accelerated interest in digital twins, showcasing their potential during urgent scientific challenges.
Conclusion:
The continuing integration of digital twin technologies in biopharma holds promise for enhanced predictive capabilities in drug development. Future applications may lead to transformative changes in clinical trial methodologies and drug efficacy assessments, driven by ongoing advancements in AI and supportive regulatory frameworks.
